BioSpace News Archive

BELLUS Health Inc. announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, November 20, 2019 at the Jefferies Global Healthcare Conference in London.

BT5528 targets EphA2, an antigen believed to be overexpressed in tumor types with high unmet need and a target for which antibody-based approaches have been unsuccessful to date

ADMA Biologics, Inc. announced that Adam Grossman, President and Chief Executive Officer, is scheduled to present a corporate overview at the Jefferies 2019 London Healthcare Conference, to be held November 20-21, 2019, at the Waldorf Hilton London, UK. ADMA is scheduled to present on Wednesday, November 20, 2019 at 8:00 AM GMT.

Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Company management will present at the following investor conferences

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2019.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on the status of its development programs.

Abbott (NYSE: ABT) today announced that Miles D. White will be stepping down as Chief Executive Officer on March 31, 2020, after a remarkable 21-year tenure, the second longest for a non-founder in today’s S&P 100. He will remain Executive Chairman of the Board.

Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), today provided a business update and announced its operating and financial results for the second quarter of fiscal 2020 ended September 30, 2019.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences

Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) is pleased to announce that the Corporation has become a member of BIOTECanada, a national industry association with over 200 members that represents Canada’s health, industrial and agricultural biotechnology sectors.